Nanoscale drug delivery vehicles for solid tumors: A new paradigm for localized drug delivery using temperature sensitive liposomes

Nanotechnology for Cancer Therapy

Volumn , Issue , 2006, Pages 677-719

  Needham, David ^a   Ponce, Ana ^a  

^a Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132526751     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (177)

1. National Library of Medicine. ClinicalTrials.gov [cited Feb 2006]; Available from: http://www.clinicaltrials.gov/.
2. Gabizon, A. A., Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet, Clin. Cancer Res., 7(2), 223-225, 2001.
3. Riethmiller, S., From atoxyl to salvarsan: Searching for the magic bullet, Chemotherapy, 51 (5), 234-242, 2005.
4. Holland, J. et al., Principles of medical oncology, In Cancer Medicine, Bast, R. et al., Eds., B.C. Decker Inc., Hamilton, Ont., 2003.
5. Willmott, N. and Daly, J., Microspheres and Regional Cancer Therapy, CRC Press Inc., Boca Raton, FL, 1994.
6. Almond, B. A. et al., Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer, J. Control. Release, 91(1-2), 147-155, 2003.
7. Rhines, L. D. et al., Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: Anovel treatment for experimental malignant glioma, Neurosurgery, 52(4), 872-879, 2003. discussion 879-880.
8. Allen, T. M. and Cullis, P. R., Drug delivery systems: Entering the mainstream, Science, 303(5665), 1818-1822, 2004.
9. Yuan, F. et al., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in ahuman tumor xenograft, Cancer Res., 54(13), 3352-3356, 1994.
10. Hobbs, S. K. et al., Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, Proc. Natl Acad. Sci. U.S.A., 95(8), 4607-1612, 1998.
11. Torchilin, V. P., Targeted polymeric micelles for delivery of poorly soluble drugs, Cell. Mol. Life Sci., 61(19-20), 2549-2559, 2004.
12. Wang, J., Mongayt, D., and Torchilin, V. P., Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids, J. Drug Target., 13(1), 73-80, 2005.
13. Kabanov, A. V., Batrakova, E. V., and Alakhov, V. Y., Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery, J. Control. Release, 82(2-3), 189-212, 2002.
14. Rangel-Yagui, C. O., Pessoa, A. Jr., and Tavares, L. C., Micellar solubilization of drugs, J. Pharm. Pharm. Sci., 8(2), 147-165, 2005.
15. Allen, T. M., Liposomal drug formulations. Rationale for development and what we can expect for the future, Drugs, 56(5), 747-756, 1998.
16. Drummond, D. C. et al., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol. Rev., 51(4), 691-743, 1999.
17. Discher, B. M. et al., Polymersomes: Tough vesicles made from diblock copolymers, Science, 284 (5417), 1143-1146, 1999.
18. Dharap, S. S. et al., Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, J. Control. Release, 91(1-2), 61-73, 2003.
19. Kopecek, J. et al., Water soluble polymers in tumor targeted delivery, J. Control. Release, 74(1-3), 147-158, 2001.
20. Duncan, R. et al., Polymer-drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to clinic, J. Control. Release, 74(1-3), 135-146, 2001.
21. Vasey, P. A. et al., Phase Iclinical and pharmacokinetic study of PK1 [iV-(2--hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of anew class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee, Clin. Cancer Res., 5(1), 83-94, 1999.
22. Patri, A. K., Kukowska-Latallo, J. F., and Baker, J. R. Jr., Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex, Adv. Drug Deliv. Rev., 57(15), 2203-2214, 2005.
23. Choi, Y. and Baker, J. R. Jr., Targeting cancer cells with DNA-assembled dendrimers: Amix and match strategy for cancer, Cell Cycle, 4(5), 669-671, 2005.
24. Wong, J. Y. et al., APhase Itrial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radio-immunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer, Clin. Cancer Res., 9(16 Pt 1), 5842-5852, 2003.
25. Juweid, M. E., Radioimmunotherapy of B-cell non-hodgkin's lymphoma: From clinical trials to clinical practice, J. Nucl. Med., 43(11), 1507-1529, 2002.
26. Gabizon, A. A. et al., Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies, Cancer Investig., 22(5), 663-669, 2004.
27. Berry, G. et al., The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin, Ann. Oncol., 9(7), 711-716, 1998.
28. Harris, L. et al., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94(1), 25-36, 2002.
29. Working, P. K. et al., Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes, J. Pharmacol. Exp. Ther., 289(2), 1128-1133, 1999.
30. Papahadjopoulos, D. et al., Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl Acad. Sci. KS.A., 88(24), 11460-11464, 1991.
31. Maeda, H. et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review, J. Control. Release, 65(1-2), 271-284, 2000.
32. Allen, T. M. et al., Adventures in targeting, J. Liposome Res., 12(1-2), 5-12, 2002.
33. Bendas, G., Immunoliposomes: Apromising approach to targeting cancer therapy, BioDrugs, 15(4), 215-224, 2001.
34. Zevalin Injection (Ibritumomab Tiuxetan) Drug Information.[cited; Available from: http://www.drugs.com/, 2005.
35. Witzig, T. E. et al., Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radio-immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, J. Clin. Oncol., 20(10), 2453-2463, 2002.
36. Witzig, T. E. et al., Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma, J. Clin. Oncol., 21(7), 1263-1270, 2003.
37. Nademanee, A. et al., Aphase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma, Blood, 106 (8), 2896-2902, 2005.
38. Schilder, R. et al., Follow-up results of aphase II study of ibritumomab tiuxetan radioimmu-notherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia, Cancer Biother. Radiopharm., 19(4), 478-481, 2004.
39. Wiseman, G. A. et al., Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: Aphase II multicenter trial, Blood, 99(12), 4336-4342, 2002.
40. Gibbs, W. J., Drew, R. H., and Perfect, J. R., Liposomal amphotericin B: Clinical experience and perspectives, Expert Rev. Anti. Infect. Ther., 3(2), 167-181, 2005.
41. Astellas Pharma, US., Inc. [cited Feb 2006]; Available from: http://www.astellas.us/press_room/docs/corp_brochure033105.pdf.
42. Becker, M. J. et al., Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response, J. Antimicrob. Chemother., 49, 813-820, 2002.
43. Schwartz, R. A., Lambert, W. C., Kaposi Sarcoma, Voorhees, A. V. et al., Eds., eMedicine.com, Inc, 2005.
44. Armstrong, D. K., Relapsed ovarian cancer: Challenges and management strategies for achronic disease, Oncologist, 7(suppl. 5), 20-28, 2002.
45. Johnston, S. R. and Gore, M. E., Caelyx: Phase II studies in ovarian cancer, Eur. J. Cancer, 37(suppl. 9), S8-S14, 2001.
46. Gordon, A. N. et al., Recurrent epithelial ovarian carcinoma: Arandomized phase III study of pegylated liposomal doxorubicin versus topotecan, J. Clin. Oncol., 19(14), 3312-3322, 2001.
47. Berek, J. S. and Bast, R. C., Ovarian cancer, In Cancer Medicine, Bast, R. et al., Eds., B.C. Decker Inc., Hamilton, Ont., 2003.
48. O'Brien, M. E. et al., Reduced cardiotoxicity and comparable efficacy in aphase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol., 15(3), 440-149, 2004.
49. Muggia, F. M., Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers, Drugs, 54(suppl. 4), 22-29, 1997.
50. Hauck, M. L., Larue, S. M., et al. Phase Itrial of doxorubicin-containing low-temperature sensitive liposomes in spontaneous canine tumors, Clin. Cancer Res., 12(13) 4004-4010, 2006.
51. Bangham, A. D., Standish, M. M., and Watkins, J. C., Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13(1), 238-252, 1965.
52. Gregoriadis, G. et al., Drug-carrier potential of liposomes in cancer chemotherapy, Lancet, 1(7870), 1313-1316, 1974.
53. Celsion Corp. [cited Feb 2006]; Available from: www.celsion.com/technology/thermodox.cfm.
54. Chen, Q. et al., Targeting tumor microvessels using doxorubicin encapsulated in anovel thermo-sensitive liposome, Mol. Cancer Ther., 3(10), 1311-1317, 2004.
55. Allen, T. M. and Smuckler, E. A., Liver pathology accompanying chronic liposome administration in mouse, Res. Commun. Chem. Pathol. Pharmacol., 50(2), 281-290, 1985.
56. Allen, T. M. et al., Chronic liposome administration in mice: Effects on reticuloendothelial function and tissue distribution, J. Pharmacol. Exp. Ther., 229(1), 267-275, 1984.
57. Gallois, L., Fiallo, M., and Garnier-Suillerot, A., Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study, Biochim. Biophys. Acta, 1370(1), 31-40, 1998.
58. Nichols, J. W. and Deamer, D. W., Catecholamine uptake and concentration by liposomes maintaining p/gradients, Biochim. Biophys. Acta, 455(1), 269-271, 1976.
59. Mayer, L. D., Bally, M. B., and Cullis, P. R., Uptake of adriamycin into large unilamellar vesicles in response to apHgradient, Biochim. Biophys. Acta, 857(1), 123-126, 1986.
60. Costanzo, L., Board Review Series, Physiology, 2nd ed., Lippincott, Williams and Wilkins, New York, 1998.
61. Truskey, G. A., Yuan, F., and Katz, D. F., Transport Phenomena in Biological Systems, Pearson Prentice Hall, Upper Saddle River, NJ, 2004.
62. Wu, N. Z. et al., Measurement of material extravasation in microvascular networks using fluorescence video-microscopy, Microvasc. Res., 46(2), 231-253, 1993.
63. Takakura, Y., Mahato, R. I., and Hashida, M., Extravasation of macromolecules, Adv. Drug Deliv. Rev., 34(1), 93-108, 1998.
64. Gerlowski, L. E. and Jain, R. K., Effect of hyperthermia on microvascular permeability to macro-molecules in normal and tumor tissues, Int. J. Microcirc. Clin. Exp., 4(4), 363-372, 1985.
65. Wu, N. Z. et al., Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue, Cancer Res., 53(16), 3765-3770, 1993.
66. Monsky, W. L. et al., Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor, Cancer Res., 59(16), 4129-H35, 1999.
67. DaunoXome Injection Drug Information. [cited; Available from: http://www.drugs.com/], 2005.
68. Dvorak, H. F. et al., Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules, Am. J. Pathol., 133(1), 95-109, 1988.
69. Yuan, F., Transvascular drug delivery in solid tumors, Semin. Radiat. Oncol., 8(3), 164-175, 1998.
70. Yuan, F. et al., Vascular permeability in ahuman tumor xenograft: Molecular size dependence and cutoffsize, Cancer Res., 55(17), 3752-3756, 1995.
71. Kong, G., Braun, R. D., and Dewhirst, M. W., Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size, Cancer Res., 60(16), 4440-4445, 2000.
72. Slater, L. M. et al., Cyclosporin Acorrects daunorubicin resistance in ehrlich ascites carcinoma, Br. J. Cancer, 54(2), 235-238, 1986.
73. Rivera, E., Liposomal anthracyclines in metastatic breast cancer: Clinical update, Oncologist, 8 (Suppl 2), 3-9, 2003.
74. Bradley, A. J. and Devine, D. V., The complement system in liposome clearance: Can complement deposition be inhibited?, Adv. Drug Deliv. Rev., 32(1-2), 19-29, 1998.
75. Allen, T. M., Hansen, C., and Rutledge, J., Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues, Biochim. Biophys. Acta, 981(1), 27-35, 1989.
76. Moghimi, S. M. et al., Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating, Biochem. Biophys. Res. Commun., 177(2), 861-866, 1991.
77. Alving, C. R. et al., Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs, Proc. Natl Acad. Sci. U.S.A., 75(6), 2959-2963, 1978.
78. New, R. R. et al., Antileishmanial activity of antimonials entrapped in liposomes, Nature, 272(5648), 55-56, 1978.
79. Weldon, J. S. et al., Liposomal chemotherapy in visceral leishmaniasis: An ultrastructural study of an intracellular pathway, Z. Parasitenkd., 69(4), 415-424, 1983.
80. Berman, J. D., U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis, Clin. Infect. Dis., 28(1), 49-51, 1999.
81. Catania, S. et al., Visceral leishmaniasis treated with liposomal amphotericin B, Pediatr. Infect. Dis. J., 18(1), 73-74, 1999.
82. Allen, T. M. et al., Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta, 1066(1), 29-36, 1991.
83. Gabizon, A. and Martin, F., Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours, Drugs, 54(suppl. 4), 15-21, 1997.
84. Gabizon, A. et al., In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice, Clin. Cancer Res., 9(17), 6551-6559, 2003.
85. Bedu-Addo, F. K. et al., Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: Implications in liposomal drug delivery, Pharm. Res., 13(5), 710-717, 1996.
86. Torchilin, V. P. et al., Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium, FASEB J., 6(9), 2716-2719, 1992.
87. Needham, D., McIntosh, T. J., and Lasic, D. D., Repulsive interactions and mechanical stability of polymer-grafted lipid membranes, Biochim. Biophys. Acta, 1108(1), 40-48, 1992.
88. Needham, D., McIntosh, T. J., and Zhelev, D. V., Surface chemistry of the sterically stabilized PEG-liposome: General principles, In Liposomes: Rational Design, Janoff, A., Ed., Marcel Dekker, Inc., New York, pp. 13-62, 1999.
89. Mori, A. and Huang, L., "Ninja" liposomes avoiding reticuloendothelial system: Development and application, In First Shizuoka Drug Delivery System Symposium. Progress in Drug Delivery Systems, University of Shizuoka, Japan, 1992.
90. Mori, A. et al., Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo, FEBS Lett., 284(2), 263-266, 1991.
91. Allen, C. et al., Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol), Biosci. Rep., 22(2), 225-250, 2002.
92. Papahadjopoulos, D. and Gabizon, A., Liposomes designed to avoid the reticuloendothelial system, Prog. Clin. Biol. Res., 343, 85-93, 1990.
93. Vaage, J. et al., Chemoprevention and therapy of mouse mammary carcinomas with doxorubicin encapsulated in sterically stabilized liposomes, Cancer, 73(9), 2366-2371, 1994.
94. Vaage, J. et al., Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes, Cancer, 72(12), 3671-3675, 1993.
95. Vaage, J. et al., Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts, Cancer, 73(5), 1478-1484, 1994.
96. Vaage, J. et al., Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against axenografted human pancreatic carcinoma, Br. J. Cancer, 75(4), 482-486, 1997.
97. Doxil Injection Drug Information. [cited; Available from: http://www.drugs.com/], 2005.
98. Kong, G. et al., Efficacy of liposomes and hyperthermia in ahuman tumor xenograft model: Importance of triggered drug release, Cancer Res., 60(24), 6950-6957, 2000.
99. Needham, D. and Nunn, R. S., Elastic deformation and failure of lipid bilayer membranes containing cholesterol, Biophys. J., 58(4), 997-1009, 1990.
100. INEX and Enzon announce FDA acceptance of Onco TCS New Drug Application. [cited Feb 2006]; Available from: http://www.drugs.com/NDA/onco_tcs_040521.html, 2004.
101. Krishna, R. et al., Liposomal and nonliposomal drug pharmacokinetics after administration of lipo-some-encapsulated vincristine and their contribution to drug tissue distribution properties, J. Pharmacol. Exp. Ther., 298(3), 1206-1212, 2001.
102. Gelmon, K. A. et al., Phase Istudy of liposomal vincristine, J. Clin. Oncol., 17(2), 697-705, 1999.
103. Sarris, A. H. et al., Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial, Ann. Oncol., 11(1), 69-72, 2000.
104. Vincristine liposomal-INEX: Lipid-encapsulated vincristine, onco TCS, transmembrane carrier system-vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. Drugs RD, 5(2): p. 119-23, 2004.
105. Huang, Q. et al., Noninvasive visualization of tumors in rodent dorsal skin window chambers, Nat. Biotechnol., 17, 1033-1035, 1999.
106. Matteucci, M. L. et al., Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas, Clin. Cancer Res., 6(9), 3748-3755, 2000.
107. Evans, E. and Needham, D., Physical-properties of surfactant bilayer-membranes-thermal transitions, elasticity, rigidity, cohesion, and colloidal interactions, J. Phys. Chem., 91(16), 4219-4228, 1987.
108. Kwok, R. and Evans, E., Thermoelasticity of large lecithin bilayer vesicles, Biophys. J., 35(3), 637-652, 1981.
109. Kong, G., Braun, R. D., and Dewhirst, M. W., Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature, Cancer Res., 61(7), 3027-3032, 2001.
110. Wu, N. Z. et al., Simultaneous measurement of liposome extravasation and content release in tumors, Microcirculation, 4(1), 83-101, 1997.
111. Fung, V. W., Chiu, G. N., and Mayer, L. D., Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors, Biochim. Biophys. Acta, 1611(1-2), 63-69, 2003.
112. Satchi-Fainaro, R. et al., PDEPT: Polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as amodel combination, Bioconjug. Chem., 14(4), 797-804, 2003.
113. Satchi, R., Connors, T. A., and Duncan, R., PDEPT: Polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin Band PK1 as amodel combination, Br. J. Cancer, 85(7), 1070-1076, 2001.
114. Needham, D. and Dewhirst, M. W., The development and testing of anew temperature-sensitive drug delivery system for the treatment of solid tumors, Adv. Drug Deliv. Rev., 53(3), 285-305, 2001.
115. Mills, J. K. and Needham, D., Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition, Biochim. Biophys. Acta, 1716(2), 77-96, 2005.
116. Rensen, P. C. et al., Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo, J. Biol. Chem., 276 (40), 37577-37584, 2001.
117. Kong, G. and Dewhirst, M. W., Hyperthermia and liposomes, Int. J. Hyperthermia, 15(5), 345-370, 1999.
118. Dewhirst, M. et al., Hyperthermia, In Cancer Medicine, Bast, R. et al., Eds., B.C. Decker Inc., Hamilton, Ont., 2003.
119. Herman, T. S. et al., Effect of heating on lethality dueto hyperthermia and selected chemotherapeutic drugs, J. Natl Cancer Inst., 68(3), 487-491, 1982.
120. Estimated incidence, mortality, and site of failure of the most common types of cancer in the United States in 2001. Cancer Facts and Figure 2001 in Atlanta: American Cancer Society. 2001.
121. Suit, H., Assessment of the impact of local control on clinical outcome, Front Radiat. Ther. Oncol., 29, 17-23, 1996.
122. Schmidt-Ullrich, R., Local tumor control and survival: Clinical evidence and tumor biologic basis, Surg. Oncol. Clin. N. Am., 9(3), 401-404, 2000. See also page vii.
123. Needham, D. et al., Anew temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in ahuman tumor xenograft model, Cancer Res., 60(5), 1197-1201, 2000.
124. Haest, C. W. et al., Fragility of the permeability barrier of Escherichia coli, Biochim. Biophys. Acta, 288(1), 43-53, 1972.
125. Papahadjopoulos, D. et al., Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol, Biochim. Biophys. Acta, 311(3), 330-348, 1973.
126. Mouritsen, O. G., Jorgensen, K., and Honger, T., Permeability of lipid bilayers near the phase transition, In Permeability and Stability of Lipid Bilayers, Disalvo, E. A. and Simon, S. A., Eds., CRC Press, Boca Raton, pp. 137-160, 1995.
127. Mouritsen, O. G. and Zuckermann, M. J., Model of interfacial melting, Phys. Rev. Lett., 58(4), 389-392, 1987.
128. Marsh, D., Watts, A., and Knowles, P. F., Evidence for phase boundary lipid. Permeability of tempo-choline into dimyristoylphosphatidylcholine vesicles at the phase transition, Biochemistry, 15, 3570-3578, 1976.
129. Corvera, E. et al., The permeability and the effect of acyl-chain length for phospholipid bilayers containing cholesterol: Theory and experiment, Biochim. Biophys. Acta, 1107, 261-270, 1991.
130. Nagle, J. F. and Scott, H. L. Jr., Lateral compressibility of lipid mono- and bilayers. Theory of membrane permeability, Biochim. Biophys. Acta, 513(2), 236-243, 1978.
131. Doniach, S., Thermodynamic fluctuations in phospholipid bilayers, J. Chem. Phys., 68, 4912-4916, 1978.
132. Jacobson, K. and Papahadjopoulos, D., Phase transitions and phase separations in phospholipid membranes induced by changes in temperature, pH, and concentration of bivalent cations, Biochemistry, 14(1), 152-161, 1975.
133. Yatvin, M. B. et al., Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202(4374), 1290-1293, 1978.
134. Magin, R. L. and Niesman, M. R., Temperature-dependent permeability of large unilamellar liposomes, Chem. Phys. Lipids, 34(3), 245-256, 1984.
135. Gaber, M. H., Effect of bovine serum on the phase transition temperature of cholesterol-containing liposomes, J. Microencapsul., 15(2), 207-214, 1998.
136. Ipsen, J. H. and Mouritsen, O. G., Modelling the phase equilibria in two-component membranes of phospholipids with different acyl-chain lengths, Biochim. Biophys. Acta, 944(2), 121-134, 1988.
137. Marsh, D., CRC Handbook of Lipid Bilayers, CRC Press, Boca Raton, 1990.
138. von Dreele, P. H., Estimation of lateral species separation from phase transitions in nonideal two-dimensional lipid mixtures, Biochemistry, 17(19), 3939-3943, 1978.
139. Bloom, M., Evans, E., and Mouritsen, O. G., Physical properties of the fluid lipid-bilayer component of cell membranes: A perspective, Q. Rev. Biophys., 24(3), 293-397, 1991.
140. Zhelev, D. V. and Needham, D., Tension-stabilized pores in giant vesicles: Determination of pore size and pore line tension, Biochim. Biophys. Acta, 1147(1), 89-104, 1993.
141. Olbrich, K., Water permeability and mechanical properties of unsaturated lipid membranes and sarcolemma vesicles, In Mechanical Engineering and Materials Science. Duke University: Durham, NC, 1997.
142. Needham, D., Stoicheva, N., and Zhelev, D. V., Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid, Biophys. J., 73(5), 2615-2629, 1997.
143. Needham, D. and Evans, E., Structure and mechanical properties of giant lipid (DMPC) vesicle bilayers from 20 degrees Cbelow to 10 degrees Cabove the liquid crystal-crystalline phase transition at 24 degrees C, Biochemistry, 27(21), 8261-8269, 1988.
144. Needham, D., McIntosh, T. J., and Evans, E., Thermomechanical and transition properties of dimyr-istoylphosphatidylcholine/cholesterol bilayers, Biochemistry, 27(13), 4668-4673, 1988.
145. Kim, D. and Needham, D. Lipid bilayers and monolayers: Characterization using micropipet manipulation techniques. In Encyclopedia of Surface and Colloid Science, Somasundaran, P., Hubbard, A., Et al., Eds., Marcel Dekker, New York, pp. 3057-3086, 2002.
146. Needham, D. and Zhelev, D., The mechanochemistry of lipid vesicles examined by micropipet manipulation techniques, In Vesicles, Rosoff, B., Ed., Macel Dekker, New York, 1996.
147. Needham, D. and Zhelev, D., Use of micropipet manipulation techniques to measure the properties of giant lipid vesicles, In Giant Vesicles, Luisi, P. L., Walde, P., Eds., Wiley, New York, 2000.
148. Anyarambhatla, G. R. and Needham, D., Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: Anew temperature-sensitive liposome for use with mild hyperthermia, J. Liposome Res., 9(4), 491-506, 1999.
149. Ickenstein, L. M. et al., Disc formation in cholesterol-free liposomes during phase transition, Biochim. Biophys. Acta, 1614(2), 135-138, 2003.
150. Kruijff, B. D., Demel, R. A., and Deenen, L. L. M. V., The effect of cholesterol and epicholesterol incorporation on the permeability and on the phase transition of intact Acholeplasma laidlawii cell membranes and derived liposomes, Biochim. Biophys. Acta, 255, 331-347, 1972.
151. Kim, D. H. et al., Mechanical properties and microstructure of polycrystalline phospholipid mono-layer shells: Novel solid microparticles, Langmuir, 19(20), 8455-8466, 2003.
152. Simon, S. A. et al., Increased adhesion between neutral lipid bilayers: Interbilayer bridges formed by tannic acid, Biophys. J., 66(6), 1943-1958, 1994.
153. Zhelev, D. V. et al., Interaction of synthetic HA2 influenza fusion peptide analog with model membranes, Biophys. J., 81(1), 285-304, 2001.
154. Zhelev, D. V., Exchange of monooleoylphosphatidylcholine with single egg phosphatidylcholine vesicle membranes, Biophys. J., 71(1), 257-273, 1996.
155. Wright, A. M., Ickenstein, L. M., and Needham, D. Optimization of athermosensitive liposome formulation for doxorubicin, in preparation.
156. Langner, M. and Hui, S. W., Dithionite penetration through phospholipid bilayers as ameasure of defects in lipid molecular packing, Chem. Phys. Lipids, 65(1), 23-30, 1993.
157. Langner, M. and Hui, S., Effect of free fatty acids on the permeability of 1, 2-dimyristoyl-sn-glycero-3-phosphocholine bilayer at the main phase transition, Biochim. Biophys. Acta, 1463(2), 439-447, 2000.
158. Zhelev, D. V. and Needham, D., Pore formation and pore dynamics in bilayer membranes, ASME. Adv. Heat Mass Transfer Biotechnol., 34, 47-49, 1996.
159. Madden, T. D. et al., The accumulation of drugs within large unilamellar vesicles exhibiting aproton gradient: Asurvey, Chem. Phys. Lipids, 53(1), 37-46, 1990.
160. Wright, A., Drug loading and release from athermally sensitive liposome. In Mechanical Engineering and Materials Science. Duke University, Durham, NC, 2006.
161. Wright, A. M., Ickenstein, L. M., and Needham, D., Optimization of athermosensitive liposome formulation for doxorubicin (in preparation Feb 2006).
162. Gaber, M. H. et al., Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks, Int. J. Radiat. Oncol. Biol. Phys., 36(5), 1177-1187, 1996.
163. Gaber, M. H., Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia, J. Biochem. Mol. Biol. Biophys., 6(5), 309-314, 2002.
164. Zhao, Y. et al., Comparative effects of anovel thermosensitive doxorubicin-containing liposome in human and mouse tumors. Mol. Cancer Ther. (to be submitted March 2006).
165. Owen, C. S., Dependence of proton generation on aerobic or anaerobic metabolism and implications for tumour pH, Int. J. Hyperthermia, 12(4), 495-499, 1996.
166. Braun, R. D. et al., Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents, Am. J. Physiol. Heart Circ. Physiol., 280(6), H2533-H2544, 2001.
167. Teicher, B. A. et al., Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma, Cancer Res., 50(11), 3339-3344, 1990.
168. Viglianti, B. L. et al., In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery, Magn. Reson. Med. 51(6), 1153-62, 2004.
169. Viglianti, B. L. et al., Chemodosimetry of in-vivo tumor liposomal drug concentration using MRI, J. Magn. Reson. Imaging, in press.
170. Ponce, A. M. et al., Temperature-sensitive liposome release observed by MRI: Drug dose painting with hyperthermia impacts anti-tumor effect. Clin. Cancer Res. in press.
171. Jensen, S. S. et al., Secretory phospholipase A2 as atumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids, Mol. Cancer Ther., 3(11), 1451-1458, 2004.
172. Liposome. 1999 [cited Feb 2006]; Available from: http://www.uic.edu/classes/bios/bios100/lectf03am/liposome.jpg.
173. O'Driscoll, C., and Duncan, R., Chembytes e-zine: Stealth drugs take off2000 [cited Feb 2006]; Available from: http://www.chemsoc.org/chembytes/ezine/2000/odriscoll_nov00.htm.
174. Heather Bullen Research Group, Northern Kentucky University [cited Feb 2006]; Available from: http://www.nku.edu/ ~ bullenh1/research.htm.
175. Kukowska-Latallo, J. F. et al., Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer, Cancer Res., 65(12), 5317-5324, 2005.
176. Klement, A., TARA News, High-Tech. Behandlung bei malignem Lymphom: Zevalin. 2004 [cited; Available from: http://www.oeaz.at/zeitung/3aktuell/2004/17/serie/serie17_2004tara.html.
177. Hyperthermia at University of California-San Francisco. [cited Feb 2006.]; Available from: http://www.ucsfhyperthermia.org/patientinfo/hyperucsf.htm.